Sanofi and GSK announced the postponement of their adjuvant recombinant protein-
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.
A recent challenge study in non-human primates performed with an improved antigen formulation demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs, within 2 to 4 days. These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults.
You May Interested In
Glow70/KLOW80 99% China Peptides Warehouse Direct Delivery Lyophilized Powder in Stock
$1.8E+2/UNIT FOB
2026-08-16
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Sanofi and Translate Bio mRNA COVID-19 vaccine candidate induced high antibody
-
Sanofi and GSK will supply up to 300 million doses of COVID-19 vaccine to EU
-
Sanofi and GSK will supply up to 300 million doses of COVID-19 vaccine to EU
-
Univar Solutions and BASF Expand Distribution Agreement
-
L'Oréal to Invest $80 Million in Mexico Factory Expansion
-
Eastman and Huafon Chemical to Establish Cellulose Acetate Yarn Production Plant in China
-
EPA Reviews Bayer’s New Fungicide Fluoxapiprolin for US Crops Disease Control Expanded Risk Assessed as Low
-
Brazil Launches EficazControl Biocontrol Agent Yields Up 3.71 Bags per Hectare Approved for Soybean Corn Disease Protection
-
Eli Lilly to Raise UK Mounjaro Price 170 Percent Monthly Cost Jumps from £122 to £330
-
Eli Lilly Strikes $1.3 Billion AI Deal with Superluminal for Next-Gen Obesity Drugs Targets GPCR Breakthrough
Recommend Reading
-
Syensqo Q2 Net Sales Down 7 Percent EBITDA Margin Rises to 21 Percent US Listing and Business Divestiture Announced
-
Novo Nordisk Launches Wegovy in South Africa One in Two Adults Faces Obesity as GLP-1 Drug Competition Heats Up
-
Huajin Aramco Mega Project Sees 11 Units Completed in One Day 83.7 Billion Yuan Investment Enters Production Prep Phase
-
Sinopec and Técnicas Reunidas Secure 4GW Green Hydrogen FEED Contract for Saudi Yanbu Project Global Capacity Record Set for 2030
-
Saipem Eyes $20 Billion Mozambique LNG Restart and 39 Percent EBITDA Surge Merger with Subsea7 Moves Forward
-
Costs Decline, Supply Remains Abundant—DOP Prices Fluctuate and Fall This Week
-
Supply Strong, Demand Weak: ABS Prices Fall in Mid-August in China
-
Positive Factors Boost Polyethylene to Operate Slightly Stronger
-
Cost Center Shifts Downward, PTA Prices Remain Weak
-
This Week's PVC Prices Narrowly Declined in China